Interpretation Builder

Generate professional clinical interpretations for blood bank workups with automatic compatibility calculations.

Case & Findings

Case Setup

Pick a case type or common scenario — or choose from the full Special scenario list below.

WOCBP / HDFN applies

Special scenario (full list)

Patient Rh(D) type

Load example antibodies

Examples fill sample inputs for training or a fast starting point. Review and adjust before copying.

Paste antibodies or workup text

Antibody Findings

Antibodies Identified

Type and select antigens, or use quick-add buttons below

Quick Add - Common Antibodies:

Cold-reactive antibody detected

Is this patient scheduled for a procedure associated with systemic hypothermia or cold cardioplegia (e.g., cardiac surgery on cardiopulmonary bypass, or aortic/arch repair with deep hypothermic circulatory arrest)? If so, check the box below — cold-reactive alloantibodies require antigen-negative units regardless of prewarm results, and the cold-agglutinin guidance is expanded for perioperative coordination.

Planned hypothermic / cold cardioplegia surgery

Anti-A1 found through an ABO typing discrepancy (antibody screen negative)

A1 lectin result

Prints the ABO-discrepancy sign-out when anti-A1 is the only finding and the A1 lectin is negative. Otherwise the standard anti-A1 report prints, with a warning.

Identified only with enzyme-treated reagent red cells

Enzyme

Include Previously Identified Antibodies

Enable to designate which antibodies were previously identified. Click on an antibody tag to toggle its status.

Blue tags = Newly identified | Gray dashed tags = Previously identified | Click to hide significance text | Click OSH to flag an antibody as reported by an outside facility

Click any antibody tag above to toggle between new and previously identified

Outside-facility cold antibodies — manage as clinically significant

When checked, the antibody is treated as potentially warm-reactive (warm reactivity not excluded at the outside facility) and requires antigen-negative units. When unchecked, standard graduated handling applies (antigen-negative only if AHG crossmatch-compatibility cannot be achieved, unless it is tested and does not prewarm away).

Thermal Reactivity & Prewarming

Record the 37°C settled prewarm result per cold specificity. PREW non-reactive at 37°C and AHG · NPREW reactive at 37°C and/or AHG · Not performed will not be done on this specimen (reported as such, unlike “not recorded”).

Anti-M: the cascade turns on the 37°C/AHG phases of LISS. IS/RT-only reactivity does not call for M-negative units; 37°C/AHG reactivity goes to prewarming, and only NPREW makes M-negative firm. The prewarm rung appears once that reactivity is entered.

With an autoantibody: record a prewarm result only when it was read on adsorbed plasma. A prewarms-away (PREW) result counts only on a panreactive current workup, which reports its plasma adsorption; otherwise the antibody is treated as not prewarm-tested.

Autoantibody Auto?

Mode

Panreactive (full workup)

Auto with specificity

Autoantibody class

Warm

Cold

Provenance

Current workup

Previously identified (in-house)

Identified at outside facility

Include significance note

Autoantibody Specificity

Which antigen(s) does the autoantibody show specificity for? Select one or more.

RBC transfusion in the past 3 months

Asked because an autologous adsorption is recorded: transfused red cells can adsorb an alloantibody, so the report warns when the adsorption follows an RBC transfusion in the past 3 months, or when that history is unknown.

How the antigen type was obtained

A serologic type obtained within 3 months of an RBC or granulocyte transfusion, or with that history unknown, does not establish an autoantibody, and an antigen-negative one is sent to the main antibody panel, except in Auto with specificity when the 14-day control below says Transfused within 14 days or Unknown. Reticulocyte types and genotypes are not affected. On a current workup, the Serologic phenotype statement counts as a positive serologic type for a specificity left untyped. A specificity whose type leaves it unresolved (Ag-type unknown, or a type this rule sets aside and keeps here) is planned with antigen-negative units, since an alloantibody cannot be excluded. On a current workup, so is a specificity with no type entered and none stated by the Serologic phenotype statement, unless an autologous adsorption removed all reactivity with no RBC transfusion in the past 3 months: that establishes it as an autoantibody. A specificity whose antigen is the antithetical partner of one a listed alloantibody requires (for example anti-e-like reactivity beside anti-E) is not planned antigen-negative; a warning asks for the patient's type instead. For anti-D and anti-G a positive serologic or reticulocyte type does not establish an autoantibody, because a patient with a partial D types D-positive and can make anti-D, so the specificity is planned with D-negative units (G-negative units for anti-G). A genotype establishes it, and so, on a current Panreactive workup with no RBC transfusion in the past 3 months, does an autologous adsorption that removed all reactivity; select Genotype for anti-D or anti-G only when RHD genotyping predicts a conventional D. On a current workup with the Autoantibody class Warm and the DAT entered as negative, a positive serologic or reticulocyte type of any other specificity (anti-I, anti-i, anti-IH and anti-A1 excepted) does not establish one either, unless a genotype, a positive autocontrol (Auto with specificity), or, with no RBC transfusion in the past 3 months, an eluate showing the specificity or an autologous adsorption that removed all reactivity is recorded.

Molecular Reference Lab (for cognate antigen confirmation)

Leave blank to omit the molecular-confirmation paragraph. On a current workup, entering a laboratory sets 'How the antigen type was obtained' to Genotype and each listed specificity left untyped to 'Ag-positive (auto)', except anti-D and anti-G, whose type you enter yourself. Nothing is set while a listed specificity has a type you entered. When the report stops stating the molecular analysis (the laboratory cleared, or another 'Mode' or 'Provenance' chosen), what was set is undone, except what you have changed since.

Serologic phenotype statement ?

DAT Result

IgG+/C3−

IgG+/C3+

IgG−/C3+

IgG−/C3−

Neg polyspecific

Show strength

IgG: C3:

Eluate Workup

Initial eluate result

Not performed

Panreactivity

Nonreactive

Nonspecific reactivity

Specific Ab(s)

Initial eluate specificity:

Further testing of eluate

Custom method wording

Specificity identified after further eluate testing:

Use this only when an initially panreactive eluate underwent additional testing. Plasma adsorption findings are recorded separately in Step 5.

Select at least one specificity resolved by the further eluate testing, or choose “No further testing.”

Specificity Details

Autocontrol

Gel:

PeG-AHG:

LISS:

Dropdowns auto-generate text below. You can edit the text freely. With the DAT entered as negative, a positive autocontrol counts toward calling a typed specificity (other than anti-D and anti-G) an autoantibody only while this text is the sentence the dropdowns generate and the report prints it; changing a dropdown replaces an edited text with that sentence.

Recent transfusion (within 14 days)

Governs the DAT and autocontrol caveat. Whether the antigen type on each tag above can be used is set by the 3-month control under the tags; a transfusion within 14 days also counts as within 3 months.

Phenotyping & reference-lab

Serologic workup referral ?

Blood Bank (original testing)

Reference Lab

Reference lab confirmed the finding ?

Report autocontrol here, as the local finding ?

Molecular analysis referral ?

Molecular reference lab

Serologic phenotype statement ?

Explain the antigen / antibody class ?

Transfusion opener

ABO / Rh / crossmatch

AHG crossmatch

Transfusion History

Workup Details

Hospital Blood Bank

Include IRL referral paragraph

Reference Lab

Plasma Adsorption

Plasma adsorption method

Differential warm allo-adsorption

Autologous adsorption

Cycles:

Plasma adsorption result

Findings apply to the adsorption study as a whole and are reported on the final step.

No underlying alloantibodies

Alloantibodies found

Select alloantibodies found:

Residual reactivity, no defined specificity

Include WAIHA clinical correlation

Include transfusion recommendation

Passive Anti-D from RhIg

Use when anti-D is detected and attributable to RhIg administration. Add any previously-identified coexisting antibodies (e.g., anti-Le^a) in the Antibody Findings section above and mark them as previously identified — they will appear in the header and drive the fallback-antigen transfusion clause.

Tip: If this patient is pregnant, set Patient Context → Pregnant above. The interpretation will then include the "this patient is pregnant and…" framing in the history sentence.

Provenance

Current workup

Previously identified (in-house)

Identified at outside facility

Include significance note

RhIg administration date

Pre-RhIg antibody screen date (optional)

Leave blank if no pre-RhIg screen is on record. A gap >14 days triggers the ambiguous-passive variant (with 6-month repeat-testing guidance).

Pre-RhIg screen result

Negative

Positive

Enter a screen date above to specify result.

The positive antibodies / nonspecific reactivity will be pulled from Antibody Findings → Previously Identified above.

Select at least one antibody or non-specific reactivity. Mark antibodies as previously identified in the Antibody Findings section, or check "Previously identified nonspecific reactivity" in Output Options below.

⚠ Anti-D was present on the pre-RhIg screen. This is not consistent with today's anti-D being newly passive from the current dose. Two possibilities:

Prior RhIg administration (persistent passive) — check the box below and enter the prior RhIg date if known.
Active alloimmunization — uncheck "Patient remains a candidate for RhIg" below and work up accordingly; if a linked infant had hemolytic disease, check "Linked Rh(D)-positive infant had hemolytic disease" instead.

Prior RhIg administration accounts for the pre-screen anti-D

Prior RhIg date (optional)

EMR source

Patient remains a candidate for RhIg

Uncheck only if the patient has been confirmed as having immune anti-D (per ACOG PB 181).

Linked Rh(D)-positive infant had hemolytic disease (reclassify as active alloimmunization)

Replaces the passive interpretation with active alloimmunization, future-pregnancy guidance and cited references. Enter the original report date to write an addendum instead of a full interpretation.

Delivery date

Weeks' gestation (optional)

Infant IgG DAT

Anti-D in infant plasma

Anti-D in infant eluate

Infant course

Phototherapy

IVIG

Exchange transfusion

RBC transfusion

Readmitted for persistent anemia

Addendum to report dated (blank = full interpretation)

RhIg going forward

Not indicated

Defer to obstetrics

Omit

Fetal surveillance start

Early second trimester

By 15–16 weeks

Passive Antibody from IVIG (non-ABO)

Use when a named non-ABO antibody (e.g. anti-Jk(a)) is detected shortly after IVIG and may have been passively acquired. The report reasons from the patient's own type of each antigen: antigen-positive → passive vs. autoantibody; antigen-negative or untyped → passive vs. alloimmunization. Nothing is coded on the header for the passive specificity (no antibody code exists for it). Antibodies in Antibodies Identified above that are not listed here — new, previously identified or outside-facility — are reported and carried into the plan. For passive anti-A / anti-B use the IVIg option under Output Options instead.

Report

Follow-up ends the requirement only for a specificity the patient validly types positive for; anything else stays documented.

Passively acquired specificity and the patient's type

Set the patient's type of each antigen on its tag.

Typing method

RBC transfusion within 3 months

A serologic type within 3 months of a transfusion (or with the history unknown) is printed with a donor-cell caveat and treated as not established; reticulocyte and genotype types are exempt.

Red cell genotyping

A genotype that disagrees, or shows a variant allele, is entered as the type itself: set the tag to Ag-negative or Ag-type unknown and the method to Genotype.

IVIG administration date

Sample date (optional)

Previous workup date

IVIG doses (optional, printed in parentheses)

Antibody screen before the IVIG

Screen date (optional)

Direct antiglobulin test

IgG strength

Complement strength

Eluate

Plasma

Enzyme

Explain a complement-positive DAT with a Kidd specificity the patient carries

Include expected clearance and what persistence would suggest

Recommend monitoring for hemolysis

Plan: a passive specificity the patient types positive for adds no antigen requirement (AHG crossmatch compatible units), except while genotyping is pending, when its antigen-negative units are kept until the genotype confirms the type. One typed negative or untyped gets antigen-negative units, reassessed on later samples. With the eluate set to "Same specificity" and the plasma reactive only with enzyme-treated cells or nonreactive, the report says the antibody was identified in the eluate.

HTLA-like Reactivity

Use when gel panreactivity with a negative autocontrol is referred to a reference lab, titered, and DTT-treated, and reported as HTLA-like. For a sickle cell patient, set Patient Context → Sickle cell disease above to emit the CEK (C/E/K) matching variant.

Reference laboratory

Titer (optional)

DTT treatment of reagent cells

Patient K antigen typing

When DTT abolished or diminished the reactivity, units are K-negative because anti-K cannot be excluded; a K-positive patient does not need them.

DAT

For a positive-autocontrol / warm-autoantibody component (and to resolve an outside-facility “anti-X (auto vs allo)”), also enable the Autoantibody section (Auto with specificity) above — it composes with this HTLA-like workup.

Reference Laboratory Referral (alloantibody)

Use when a local panel was panreactive with a negative autocontrol, the sample was referred to a reference laboratory, and the reference lab identified the alloantibody. Enter the identified antibody in Antibodies Identified above — it still drives antigen-negative selection, significance and compatibility. This section narrates the sequence of testing.

Originating blood bank (optional)

Panreactivity

Reference laboratory

A trailing parenthetical abbreviation — e.g. “(ARC IRL)” — is used for mentions after the first.

Serologic phenotype reported (optional)

Reference-laboratory reactivity detail (optional, free text)

Alloadsorption performed — emit the attributed rule-out

Records the alloadsorption exclusion with its high-frequency-antigen caveat. A listed adsorbed-plasma antibody also records adsorption. If neither adsorption nor selected-cell exclusion is recorded, the report states that exclusion could not be performed.

Other alloantibodies excluded with selected red cells (no adsorption)

Records the reference laboratory's selected-red-cell exclusion. When adsorption is recorded, the alloadsorption statement takes precedence. The Rule-outs complete control does not change this report's statement.

Nonspecific reactivity reported

Detected only in adsorbed plasma (optional)

These get their own sentence and are excluded from the “confirms the presence of…” list, which describes what the reference laboratory demonstrated directly.

Prewarm unable to be performed (optional)

Records that prewarm testing was attempted for a specificity but could not be completed. The antigen-negative disposition is unchanged — this only states why the thermal-amplitude question is unresolved.

Reference-laboratory DAT (optional)

Red cell genotyping

Report only the finding that resolves the antibody under workup. Incidental results from a multiplex panel (Duffy GATA, RH variants) are deliberately not emitted.

Include rare-donor sourcing paragraph (high-prevalence antigens) Add sibling / autologous donation sentence

Off by default. The wording follows published guidance and the reference laboratory's own recommendation.

Add monocyte monolayer assay sentence

Off by default. For when antigen-negative units cannot be obtained in time; it points to a Transfusion Medicine consultation and orders no test.

Unresolved Panreactivity (alloantibody exclusion not possible)

Use when a reference laboratory finished its workup but could not exclude underlying alloantibodies (e.g. an unidentified panagglutinin or HTLA-like reactivity persisted after adsorption). The report issues RBCs under Emergency Release; it does not offer Exceptional Release. Clinically significant antibodies in Antibodies Identified above — new, previously identified or reported by an outside facility — are carried into the antigen-negative requirement. Anti-M is included unless a warm component was excluded (the unresolved 37°C/AHG reactivity leaves it open); other cold-reactive specificities only when warm reactivity is documented. Clinically significant low-frequency antibodies (e.g. anti-C(w), anti-Js(a), anti-V) also get antigen-negative units, because no crossmatch can be compatible; antigens without in-house reagents come from the blood supplier. Anti-Lu(a) keeps only a crossmatch note. Patient Context (sickle cell, pregnancy), the Transfusion Recommendation section and IVIG group O selection are not used by this report.

Fill from an ARC IRL final report

Paste the report text, copied from the PDF or the LIS. Only what the report states is filled; everything else is left as it is and listed below. Transfusion history, hemolysis status and the antigens units will lack are yours to enter. The pasted text is not saved.

Originating blood bank (optional)

Reference laboratory

A trailing parenthetical abbreviation — e.g. “(ARC IRL)” — is used for mentions after the first.

Neat plasma reactive with all cells at (as reported)

37°C

LISS-AHG

Including the patient's own reticulocytes (an autoantibody in the plasma)

Adsorption

Adsorbing cells (allogeneic only, optional)

4°C cycles 37°C cycles

Adsorption removed IS/RT reactivity

State that allo-adsorption cannot exclude antibodies to high-prevalence antigens

Reactivity remaining / reported

Unidentified panagglutinin

reactive at

Possible HTLA-like (AHG)

Titer

Autoantibody (type not stated)

Probable cold autoantibody

Warm autoantibody (reported by the reference lab)

Treated reagent cells Papain 0.2 M DTT

DAT Eluate against reagent red cells

Acid eluate

Eluate against the patient's own reticulocytes

Transfusion history

Within 3 months: the eluate may reflect transfused donor red cells, and serologic typing is not used. Within 28 days: the delayed-reaction assessment is added.

When (optional, completes “history of RBC transfusion …”)

Hemolysis status (within 28 days only)

Patient antigen typing

Patient phenotype

Click an antigen to cycle: not typed → negative → positive. Serologic typing within 3 months of transfusion is not used for the plan. k is offered once K is typed positive, or for genotyping; enter any other reported k under Other antigens typed.

Other antigens typed (optional)

Reticulocytes were IgG-DAT negative

Units will lack (alloantibody not excluded)

A typed-negative result is not required. An antigen the patient types positive for is unavailable: an antibody to it would be a suspected autoantibody (or a variant antigen). K is locked on after DTT, and clinically significant antibodies identified above are added automatically.

Alloantibody + Genotyping (recent transfusion)

Use when an alloantibody is identified but the patient was recently transfused (within 3 months), producing a DAT+/autocontrol+ pattern that could be confused with warm auto. Reference-lab genotyping predicts the patient's true cognate-antigen status.

Genotyping target antibody (workup rationale)

Suggestions are drawn from newly-identified antibodies above. Type and press Enter to pick the first match.

DAT result

IgG+ / C3−

IgG+ / C3+

IgG− / C3+

IgG− / C3−

Polyspecific− (no reflex)

Autocontrol

in testing

Use free-text override

Eluate result

Negative

Panreactive

Specific

Not performed

Omit (no sentence)

Eluate specificity:

Eluate not performed: DAT is IgG-negative (eluate recovers RBC-bound IgG, so no elution is possible). The eluate sentence is suppressed regardless of selection.

Pre-transfusion DAT available

When pre-transfusion DAT is unavailable, the interpretation will emit "Pre-transfusion DAT unavailable."

⚠ Confirm relevant preceding RBC transfusion. Confirm that an RBC transfusion preceded the current serologic and any hemolysis findings and that the timing is clinically compatible with a delayed reaction. Surveillance timing, when applicable, is documented separately.

Reference laboratory

Predicted phenotype

Pick from the dropdown or choose "Custom..." for free-text entry.

Scanned-docs label

Cold Antibody / Autoantibody (unspecified)

Use when the lab detects reactivity at cold phases without identifying a specific antibody. The output label is derived automatically: "cold autoantibody" if autocontrol or DAT-C3 is positive, otherwise "cold antibody."

Phase(s) of reactivity:

Immediate spin

Room temperature

4°C

Additional findings:

Positive autocontrol

Positive DAT for C3 (reported by warm-auto DAT)

Provenance

Current workup

Previously identified (in-house)

Identified at outside facility

Include significance note

Drug Interference

Use when the patient is on a therapeutic monoclonal antibody known to interfere with pretransfusion testing. Replaces the standard transfusion paragraph with drug-specific guidance.

Drug class:

Provenance

Current workup

Previously identified (in-house)

Identified at outside facility

Include significance note

Workup state

Pre-therapy

On-therapy

Drug examples (free text)

Order code

Reference Lab

Direct antiglobulin test (DAT)

Polyspecific−

IgG−/C3−

IgG+/C3−

IgG+/C3+

IgG−/C3+

Patient had recent RBC transfusion

IRL DAT result

Polyspecific−

IgG−/C3−

IgG+/C3−

IgG+/C3+

IgG−/C3+

Adsorption result

No alloantibodies

Alloantibodies found

Adsorption result derived from selected antibodies (anti-CD38 ABID r/o is performed at the IRL).

K antigen typing

Negative

Positive

Unknown / pending / unable to type

Workup state

Pre-therapy

On-therapy

Drug examples (free text)

Order code (auto-fills with mode)

Reference Lab

Prior / Outside-Facility History

Quick history entry

Document a bolus of previously-identified or outside-facility findings — they fold onto the header lines without a full per-finding workup. Enter alloantibodies in Antibody Findings (mark them previously identified / OSH); nonspecific reactivity uses Output Options.

Warm autoantibody

Cold autoantibody

HTLA-like reactivity

Passive anti-D (RhIg)

Anti-CD38 interference

Anti-CD47 interference

Include significance notes

Off = header line only. On = append each finding's clinical-significance note.

Patient Context

Non-pregnant

Pregnant

Sickle Cell/Hemoglobinopathy

Neonate

Neonatal workup with eluate findings + maternal correlation. DAT result applies to the neonatal sample; the Antibodies Identified list above represents the eluate specificities (or the plasma specificities when no eluate was tested).

Neonatal DAT

IgG only

C3 only

IgG + C3

Negative

DAT grade

Eluate

Performed

Not tested (antibodies from plasma)

Most recent plasma sample (optional)

HDFN course (adds the course paragraph)

Phototherapy

IVIG

Exchange transfusion

RBC transfusion

Readmitted for persistent anemia

Add admission and 4-month transfusion rules

Date of birth (states the 4-month date)

Add at least one antibody above to populate maternal/neonate fields.

Account for each pregnancy-relevant antibody:

Sensitive-method-only reactivity is reported as a titer of no greater than 1. The current-evidence pathway uses a surveillance threshold of 4 for anti-K and 16 for other antibodies; the ACOG PB 192 pathway does not use anti-K titer as a fetal-status threshold. Titers display as integers. An untreated anti-M titer of 16 or more is referred to the ARC IRL for titration of DTT-treated plasma; the IgG titer recorded from that result is the one compared with the threshold.

Include paternal testing paragraph

Select antibodies to include in paternal testing:

Warm-reacting component not excluded for anti-M

Check if reactivity at 37°C and/or AHG was demonstrated and not subsequently excluded. This makes M-antigen-negative units a firm requirement and enables titer monitoring. Prefer recording the rule-out cascade under Thermal Reactivity & Prewarming, which answers this from the workup and overrides this box.

State that M-antigen negative units may be necessary when the warm-reacting component is excluded

For an anti-M that prewarms away or whose rule-out cascade excluded a warm component. Untick to leave out “If crossmatch-compatibility cannot be achieved, M-antigen negative units may be necessary.” and its donor figure. An anti-M with nothing recorded keeps the sentence.

Include anti-G evaluation paragraph

When D and C are both present, anti-G may be masquerading as anti-D+anti-C. The distinction matters because patients with anti-G still need RhIG, while patients with true anti-D do not.

Patient Antigen-Negative Phenotype (for extended matching)

Select antigens the patient is negative for. This helps generate more specific matching guidance.

Manage named cold antibodies as clinically significant (sickle cell disease)

Institutional practice, as Canadian Blood Services advises for sickle cell disease: an anti-M, anti-Le(a) or anti-Le(b) gets antigen-negative units with extended prophylactic matching, and the report says why. Unticked, the plan matches Rh and Kell. Anti-N, anti-P1 and anti-Lu(a) are not covered.

Consider Autoantibody?

is identified but the patient is not -negative. In SCD patients, this may indicate an autoantibody with specificity due to variant alleles.

Include hypothermia/cold cardioplegia warning

Include Transfusion Recommendation (handled by drug-specific transfusion paragraph)

Auto-calculate from Compatibility Calculator

Automatically includes donor compatibility statistics based on selected antibodies

Documented cold autoantibody: blood-warmer advice

Adds “If a clinically significant cold agglutinin is suspected, transfusion through a blood warmer and keeping the patient warm may be advised.” and ends the plan with “For the best estimate of time …”. Off: the plan ends with the usual turnaround interval.

Prophylactic Antigen Avoidance

Cannot Rule Out Other Antibodies

Based on the identified antibodies, some additional antibodies cannot be definitively ruled out with standard panels due to haplotype linkage or shared epitopes.

Apply prophylactic antigen avoidance

Include selected antigens in transfusion recommendation. Use this checkbox to select or deselect all.

General Practice: When an antibody cannot be definitively ruled out due to haplotype linkage, many institutions recommend prophylactically avoiding the linked antigen, especially if:

The patient phenotypes negative for the linked antigen
The patient is in a high-risk category (e.g., chronically transfused, women of childbearing potential)
Rare cells for confirmation are not readily available

Important: Always follow your local SOP and consult with your medical director when needed. Consider sending specimens to a reference lab for adsorption studies or RH genotyping if definitive identification is required.

CHECKLIST FOR INTERPRETATION WRITER

Reviewed local SOP for prophylactic avoidance Checked patient phenotype for linked antigen(s) Considered patient's clinical status and transfusion history Documented rationale if prophylactic avoidance not applied

Advanced Output Options

These mirror the quick overrides beside the generated interpretation.

Rule-outs complete ?

Include HDFN statement ? (typically relevant for women of childbearing potential)

Pregnancy guideline basis ?

Nonspecific reactivity ?

None

Current — newly identified

Previously identified (in-house)

Reported by outside facility (OSH)

Include significance note ?

Include rouleaux statement ?

Append references in interpretation ?

Reference list size when pasted ?

Nonspecific reactivity observed in (optional):

AHG phase (LISS) Gel Solid phase

Rouleaux — LISS phases affected:

IS RT 37°C

Delayed reaction — clinical assessment ?

DSTR wording requires clinically significant alloantibody reactivity newly identified in the available records; it does not assert that the antibody was newly formed. DHTR assessment may also incorporate a documented historical alloantibody.

Relevant preceding RBC transfusion confirmed: an RBC transfusion preceded the current serologic and any hemolysis findings, and the timing is clinically compatible with a delayed reaction. The optional >24-hour–28-day surveillance interval is documented separately.

Historical-antibody linkage confirmed: the documented alloantibody is plausibly implicated by corresponding antigen-positive exposure and/or supportive current serology.

Verify historical-antibody linkage. Historical antibody status alone does not establish that the antibody is implicated in the current posttransfusion event.

⚠️ Confirm relevant preceding RBC transfusion Confirm that an RBC transfusion preceded the current serologic and any hemolysis findings and that the timing is clinically compatible with a delayed reaction before finalizing the interpretation.

Append surveillance context: antibody detection and/or hemolysis onset was confirmed within >24 hours through 28 days after transfusion. This adds a labelled timing statement and does not establish diagnosis or imputability.

⚠ DAT not entered. Select the DAT result below. While it is "Not reported", the report does not mention the DAT or eluate.

DAT:

Eluate:

Eluate specificity:

Reaction evidence (linked from Autoantibody)

Edit these findings in the Autoantibody section.

Include IVIg passive antibody statement ?

Include expected duration of interference

Direct antiglobulin test:

Eluate specificity:

Patient ABO / Rh(D) type:

Name the passive specificity in the header ?

Recommend group O RBCs ?

Free-text DAT / eluate (legacy)

DAT pattern (e.g., "positive for IgG, negative for C3d"):

Eluate findings (e.g., "identified anti-A antibodies"):

Include ABO isohemagglutinin source attribution

Antibody detected:

Detected in:

No current or known history of ABO discrepancy

No known history of recent transfusion with plasma-containing products

Generated Interpretation

Patient Context

Non-pregnant

Pregnant

Sickle Cell

Neonate

Include paternal testing

Warm-reacting component not excluded for anti-M

Warm component excluded: state M-antigen negative units may be necessary

Sickle cell: manage anti-M, anti-Le(a), anti-Le(b) as clinically significant

Include anti-G evaluation

Include hypothermia warning

Output Options

Rule-outs complete

Include HDFN statement

Nonspecific reactivity

None

Current

Prev. ID (in-house)

Outside facility (OSH)

Include significance note

Include rouleaux statement

Append references in text

Reference size when pasted

Nonspecific reactivity observed in (optional):

AHG phase (LISS) Gel Solid phase

Rouleaux — LISS phases affected:

IS RT 37°C

Delayed reaction — clinical assessment

DSTR wording treats an antibody as new only to the available records; it does not assert newly formed antibody.

Relevant preceding RBC transfusion confirmed

⚠ DAT not entered. Enter the DAT result in the delayed-reaction details. While it is "Not reported", the report does not mention the DAT or eluate.

Historical-antibody linkage confirmed

Append surveillance context (>24 hours–28 days confirmed)

Include IVIg passive antibody

Ready to copy

Select antibodies to generate an interpretation

Generating interpretation...

Edited text is locked. Inputs changed, so a fresh interpretation is ready to review before replacing your edits.

Updated just now

Editable

Compatibility Calculation

Compatible Donors

therapeutic / cognate antigen-negative

Units to Screen

Rarity

Fully Matched

cognate + prophylactic

Units to Screen

Rarity

Notes

Clinical Guidance

Each interpretation element is shown below with the options/logic that determined its content.

Copied to clipboard!

Keyboard Shortcuts

/: Focus the global search box in the header
Ctrl + Enter: Copy the generated interpretation to the clipboard
Ctrl + P: Print the generated interpretation
?: Show this help panel
Esc: Close this panel / dismiss autocomplete